Items without sitelinks

From determinar.ia.br - Determine suas informações

Showing below up to 50 results in range #10,151 to #10,200.

View ( | ) (20 | 50 | 100 | 250 | 500)

  1. Lead polyneuropathy (Q102659)
  2. Unintentional exposure to or harmful effects of predominantly beta-adrenoreceptor agonists (Q102658)
  3. Jamaican neuropathy (Q102657)
  4. Jamaica ginger paralysis (Q102656)
  5. Surgically-induced corneal haze (Q102655)
  6. Arsenic polyneuropathy (Q102654)
  7. Unintentional exposure to or harmful effects of alpha-adrenoreceptor antagonists (Q102653)
  8. Polyneuropathy due to organophosphate compounds (Q102652)
  9. Unintentional exposure to or harmful effects of unspecified drugs acting on muscles (Q102651)
  10. Peripheral neuropathy due to Ciguatera toxin (Q102650)
  11. Post traumatic opacity (Q102649)
  12. Unintentional exposure to or harmful effects of other anti-common-cold drugs (Q102648)
  13. Unintentional exposure to or harmful effects of terbutaline (Q102647)
  14. Unintentional exposure to or harmful effects of expectorants (Q102646)
  15. Unintentional exposure to or harmful effects of other drugs acting on muscles (Q102645)
  16. Unintentional exposure to or harmful effects of beta-adrenoreceptor antagonists (Q102644)
  17. Unintentional exposure to or harmful effects of oxytocic drugs (Q102643)
  18. Unintentional exposure to or harmful effects of vitamin D or derivatives (Q102642)
  19. Unintentional exposure to or harmful effects of other parasympatholytics or spasmolytics (Q102641)
  20. Unintentional exposure to or harmful effects of benzothiadiazine derivatives (Q102640)
  21. Unintentional exposure to or harmful effects of bisphosphonates (Q102639)
  22. Unintentional exposure to or harmful effects of other parasympathomimetics (Q102638)
  23. Unintentional exposure to or harmful effects of ganglionic blocking drugs (Q102637)
  24. Unintentional exposure to or harmful effects of anticholinesterase agents (Q102636)
  25. Unintentional exposure to or harmful effects of mineral salts, not elsewhere classified (Q102635)
  26. Unintentional exposure to or harmful effects of other diuretics (Q102634)
  27. Unintentional exposure to or harmful effects of drugs affecting uric acid metabolism (Q102633)
  28. Unintentional exposure to or harmful effects of electrolytic, caloric or water-balance agents (Q102632)
  29. Unintentional exposure to or harmful effects of predominantly alpha-adrenoreceptor agonists (Q102631)
  30. Unintentional exposure to or harmful effects of carbonic-anhydrase inhibitors (Q102630)
  31. Unintentional exposure to or harmful effects of loop diuretics (Q102629)
  32. Unintentional exposure to or harmful effects of antidiarrhoeal drugs (Q102628)
  33. Unintentional exposure to or harmful effects of saline or osmotic laxatives (Q102627)
  34. Unintentional exposure to or harmful effects of cardiac-stimulant glycosides or drugs of similar action (Q102626)
  35. Unintentional exposure to or harmful effects of other antiprotozoal drugs (Q102625)
  36. Unintentional exposure to or harmful effects of antimycobacterial drugs (Q102624)
  37. Unintentional exposure to or harmful effects of other laxatives (Q102623)
  38. Unintentional exposure to or harmful effects of other antidysrhythmic drugs (Q102622)
  39. Unintentional exposure to or harmful effects of anthelminthics (Q102621)
  40. Unintentional exposure to or harmful effects of mineralocorticoids antagonists (Q102620)
  41. Unintentional exposure to or harmful effects of other antihypertensive drugs (Q102619)
  42. Unintentional exposure to or harmful effects of antimalarials or drugs acting on other blood protozoa (Q102618)
  43. Unintentional exposure to or harmful effects of digestants (Q102617)
  44. Unintentional exposure to or harmful effects of histamine H2-receptor blockers (Q102616)
  45. Unintentional exposure to or harmful effects of emetics (Q102615)
  46. Unintentional exposure to or harmful effects of stimulant laxatives (Q102614)
  47. Unintentional exposure to or harmful effects of calcium-channel blockers (Q102613)
  48. Unintentional exposure to or harmful effects of antihyperlipidemic or antiarteriosclerotic drugs (Q102612)
  49. Unintentional exposure to or harmful effects of mineralocorticoids (Q102611)
  50. Unintentional exposure to or harmful effects of other antacids or anti-gastric-secretion drugs (Q102610)

View ( | ) (20 | 50 | 100 | 250 | 500)

Retrieved from "https://determinar.ia.br/wiki/Special:ItemsWithoutSitelinks"